AI assistant
Nuvectis Pharma, Inc. — Director's Dealing 2025
Nov 6, 2025
33912_dirs_2025-11-06_99f71c15-0ae7-442d-a636-2cc9895dd843.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2025-11-05
Reporting Person: Sanchez Juan (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Common Stock | P | 13000 | $5.79 | Acquired | 78150 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 415 | Indirect |
Footnotes
F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.77 to $5.81. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.